Ascletis Reports ASC30 HbA1c Reduction of 1.7% at 12 Weeks

In a U.S. Phase II study in participants with diabetes, ASC30 reduced HbA1c by a placebo-adjusted 1.7%, 1.6% and 1.7% from baseline at 12 weeks for 40 mg, 60 mg and 80 mg, respectively, meeting the primary endpoint.